Particle counting immunoassay of S100 protein in serum. Possible relevance in tumors and ischemic disorders of the central nervous system.
Particle counting immunoassay of S100 protein in serum. Possible relevance in tumors and ischemic disorders of the central nervous system.
复制标题
血清中S100蛋白的粒子计数免疫分析。
作者：
O. Fagnart;C J Sindic;C. Laterre
应用免疫颗粒计数法检测了50例正常人、325例神经系统疾病患者和20例恶性黑色素瘤患者血清中S100蛋白（S100）。该蛋白的检测限为0.3 μ g/L。我们在健康个体或50名多发性硬化症患者、23名痴呆症患者或20名脑膜炎患者中未检测到。仅在少数脑膜神经根炎（2/20）、周围神经病（2/30）、脑炎（1/14）、格林-巴利综合征（1/25）或AIDS（2/20）患者血清中可检测到S100。相反，我们在75例中枢神经系统肿瘤患者中的29例中观察到高浓度，尤其是脑膜瘤（6/9），胶质母细胞瘤（9/23）和神经鞘瘤（5/5）。在脑血管疾病（43/48）或黑色素瘤转移（9/11）患者的血清中，S100值主要异常高（大于0.3 μ g/L）。
S100 protein (S100) was assayed by particle counting immunoassay in serum samples from 50 healthy individuals, 325 patients with various neurological disorders, and 20 patients with malignant melanoma. The detection limit for this protein was 0.3 microgram/L. We detected none in healthy individuals or in 50 patients with multiple sclerosis, 23 with dementia, or 20 with meningitis. S100 was detectable in serum of only a few patients with meningoradiculitis (2/20), peripheral neuropathy (2/30), encephalitis (1/14), Guillain-Barré syndrome (1/25), or AIDS (2/20). In contrast, we observed high concentrations in 29 of 75 patients with tumors of the central nervous system, especially in meningioma (6/9), glioblastoma (9/23), and neurinoma (5/5). Values for S100 were mainly abnormally high (greater than 0.3 microgram/L) in serum from patients with cerebrovascular disorders (43/48) or with metastases of melanoma (9/11).